Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
25actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-03 | actual | When the study began enrolling |
| Primary completion | 2025-02-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-19 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Intervention
- Drug: BMS-986435
Primary outcomes
what the primary-completion date above is the date OFMaximum observed plasma concentration (Cmax)
measured Up to 105 days
Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]
measured Up to 105 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
measured Up to 105 days
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed